癌症中聚(ADP-核糖)聚合酶活性的PET显像:临床前评估与首次人体研究
前瞻性研究自2012年2月至2015年7月开展,评估18F-FTT PET显像聚(ADP-核糖)聚合酶(PARP)活性的可行性。小鼠中奥拉帕利(n=14)显著降低脊柱和淋巴结的18F-FTT AUC,而伊尼帕利(n=11)无显著影响;人体有效剂量估计为6.9 mSv(370 MBq),脾和胰腺摄取最高,5例可测肿瘤中2例摄取增高。
要点
- 18F-FTT PET可显示PARP活性,奥拉帕利处理小鼠脊柱和淋巴结AUC显著降低。
- 人体有效剂量估计为6.9 mSv(370 MBq),与临床在用显像剂相容。
- 人体图像中脾和胰腺摄取最高,5例可测肿瘤中2例18F-FTT摄取增高。
核心结论
- 结果表明18F-FTT摄取反映PARP表达,其辐射剂量学特征与当前临床使用的显像剂相容。
研究设计与样本
- 前瞻性研究,自2012年2月至2015年7月开展,经当地动物研究委员会和机构审查委员会批准;小鼠奥拉帕利组n=14、伊尼帕利组n=11,另进行小鼠生物分布研究;8例癌症患者和8名健康志愿者接受显像以验证人体辐射剂量学;采用Wilcoxon符号秩检验评估小鼠治疗组间差异。
关键影像表现/征象
- 小鼠中奥拉帕利显著降低脊柱18F-FTT AUC(中位差值-17 g/mL·min,IQR 10 g/mL·min,P=.0001),伊尼帕利无显著影响(中位差值-3 g/mL·min,IQR 13 g/mL·min,P=.70)。
- 小鼠中奥拉帕利显著降低淋巴结18F-FTT AUC(中位差值-23 g/mL·min,IQR 13 g/mL·min,P=.0001),伊尼帕利无显著影响(中位差值-9 g/mL·min,IQR 17 g/mL·min,P=.05)。
- 人体图像中脾和胰腺摄取最高;5例可测肿瘤中,1例胰腺腺癌和1例肝癌可见18F-FTT摄取增高。
诊断标准与关键数值
- 18F-FTT的AUC(单位g/mL·min)用于评估正常小鼠器官在奥拉帕利或伊尼帕利治疗前后的PARP活性变化。
- 人体有效剂量估计为6.9 mSv(370 MBq 18F-FTT剂量)。
临床应用与阅片要点
- 18F-FTT PET可用于评估PARP活性,脾和胰腺为人体生理性高摄取器官,阅片时需注意。
- 在可测肿瘤中,胰腺腺癌和肝癌可见18F-FTT摄取增高,提示肿瘤PARP表达可能评估。
- 小鼠中奥拉帕利显著降低脊柱和淋巴结18F-FTT AUC,而伊尼帕利无显著影响,提示18F-FTT摄取反映PARP抑制。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Purpose To demonstrate that positron emission tomography (PET) with fluorine 18 (18F) fluorthanatrace (FTT) depicts activated poly (adenosine diphosphate-ribose)polymerase (PARP) expression and is feasible for clinical trial evaluation. Materials and Methods All studies were conducted prospectively from February 2012 through July 2015 under protocols approved by the local animal studies committee and institutional review board. The area under the receiver operating characteristic curve (AUC, in g/mL· min) for 18F-FTT was assessed in normal mouse organs before and after treatment with olaparib (n = 14), a PARP inhibitor, or iniparib (n = 11), which has no PARP inhibitory activity. Murine biodistribution studies were performed to support human translational studies. Eight human subjects with cancer and eight healthy volunteers underwent imaging to verify the human radiation dosimetry of 18F-FTT. The Wilcoxon signed rank test was used to assess for differences among treatment groups for the mouse studies. Results In mice, olaparib, but not iniparib, significantly reduced the 18F-FTT AUC in the spine (median difference before and after treatment and interquartile range [IQR]: -17 g/mL· min and 10 g/mL · min, respectively [P = .0001], for olaparib and -3 g/mL · min and 13 g/mL · min [P = .70] for iniparib) and in nodes (median difference and interquartile range [IQR] before and after treatment: -23 g/mL · min and 13 g/mL · min [P = .0001] for olaparib; -9 g/mL · min and 17 g/mL · min [P = .05] for iniparib). The effective dose was estimated at 6.9 mSv for a 370-MBq 18F-FTT dose in humans. In humans, the organs with the highest uptake on images were the spleen and pancreas. Among five subjects with measurable tumors, increased 18F-FTT uptake was seen in one subject with pancreatic adenocarcinoma and another with liver cancer. Conclusion The results suggest that 18F-FTT uptake reflects PARP expression and that its radiation dosimetry profile is compatible with those of agents currently in clinical use. © RSNA, 2016 Online supplemental material is available for this article.
引用
- Michel LS, Dyroff S, Brooks FJ, et al. PET of Poly (ADP-Ribose) Polymerase Activity in Cancer: Preclinical Assessment and First In-Human Studies. Radiology. 2016. PMID: 27841728. doi:10.1148/radiol.2016161929
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。